Ointment for treatment and prevention of alveolitis

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely, surgical dentistry and maxillofacial surgery and can be used for treatment and prevention of alveolitis. Ointment for treatment and prevention of alveolitis contains lanolin-vaseline base, crystalline iodine, water solution of potassium iodide, solcoseryl dental adhesive paste, anesthesin, polysorb MP, distilled water, with the following component ratio: lanolin-vaseline ointment 40.5-42.5; crystalline iodine 0.1-0.3; water solution of potassium iodide 0.4-0.5; solcoseryl dental adhesive paste 40.5-42.5; anesthesin 3.8-5.8; polysorb MP 0.3-0.5; distilled water - the remaining part.

EFFECT: invention makes it possible to accelerate healing of bone wounds, prevent development of inflammatory complications and reduce period of recovery of patients with alveolitis.

2 ex

 

The invention relates to medicine, namely surgical dentistry and maxillofacial surgery, and can be used for the treatment and prevention of alveolitis.

After surgery, tooth removal may be a number of complications. The most adverse of them are bone suppuration of the wound with the development of inflammation in the surrounding soft tissue (abscess, cellulitis), postoperative neuralgic pain, pain and inflammation in the hole of the extracted tooth (alveolitis). Development of methods for the treatment and prevention of such complications is an important task of dentistry.

The known method of prevention of alveolitis after tooth removal. This technique involves filling the alveolus of the tooth allogeneic placental tissue, shape and size of the corresponding hole. It accelerates the regenerative phase of healing and prevents the development of alveolitis. According to another known technique, for the prevention of alveolitis hole fill hydrophobic ointment antiseptic or antibiotic (erythromycinbuy, gettracelevel eye, gentamitsinovoy) [1].

The disadvantages of these compositions for the prevention of alveolitis is their high irritant and low biotoxicity activity against pathogenic strains of microorganisms causing alveolitis.

In kachestvenaia selected Composition for the treatment of alveolitis" (EN 2288701 C2 of 28.06.2004) [2]. In this formulation includes means providing sorption and hemostatic activity against toxins of microorganisms, products of tissue disintegration of the socket and the ability to activate regenerative processes in the stage of healing, while helping to reduce the healing time of the wound.

This technical result is achieved by including in the composition a means of benzocaine, iodine crystal, an aqueous solution of iodide of potassium, pectin, and it additionally contains analinvasion ointment. Introduction to composition for the treatment of alveolitis of iodine solution obtained by dissolving a crystal of iodine in an aqueous solution of potassium iodide and pectin increases the sorption activity of the composition contributes to the stimulation of regeneration processes.

However, the simultaneous use of crystalline iodine in aqueous solution of potassium iodide with pectin as a hemostatic element and sorbent increases local irritating action of the composition, in addition, the prototype has another serious disadvantage of poor adhesion of the medicinal components included in the composition to the wall of the alveolus of the tooth and, as a consequence, their rapid washout from the hole with saliva and blood. This lack of negates the positive properties of the composition, the reduction is the first period of its therapeutic action.

Tasked with creating ointment for the treatment and prevention of alveolitis with low irritant effect on the background of high adhesion, adsorption and antibacterial activity of the components.

The technical result - the reduction of terms of full recovery of patients by increasing the effectiveness of treatment and prevention of alveolitis claimed ointment that combines high adhesion, adsorption and antibacterial activity of its components with low irritant effect.

The problem is solved by introducing into the composition an ointment containing a local anesthetic agent, hemostatic component, antiseptic and topical basis, solcoseryl dental adhesive paste and "POLYSORB", in the following ratio, wt.%:

Lelinwalla ointment40,5-42,5
Iodine crystalof 0.1-0.3
An aqueous solution of potassium iodide0,4-0,5
Solcoseryl dental adhesive paste40,5-42,5
Benzocaineof 3.8 to 5.8
POLYSORB 0,3-0,5
Distilled waterrest

The parameters you enter in the composition of the proposed drug components was determined empirically. Introduction components below the lower or above the upper limit does not provide optimal exposure, and General appearance.

Characteristic components of the claimed ointment.

The iodine solution obtained by dissolving a crystal of iodine in an aqueous solution of potassium iodide, immobilized on the "POLYSORB", leads to the formation of iodinated organic substances, where iodine is organically bound form, which expressed its antiseptic, styptic and sorption activity, and irritant and Biologicheskie the action of elemental iodine significantly reduced.

"POLYSORB" - inorganic, non-selective, polyfunctional enterosorbent on the basis of highly dispersed silica with a particle size of from 5 to 20 nm [3]. The iodine solution, immobilized on the "POLYSORB", in addition to pronounced antiseptic properties, has a high sorption, detoxification, antioxidant and hemostatic properties, blocking aggressive free radicals. Thanks to "POLYSORB", included in the ointment provides a high CR is vostanavlivayet the ability of the entire composition.

Solcoseryl dental adhesive paste (Reg. No. 015194/01-2003) provides faster healing, pain management and protection of the wound surface. In addition, the toothpaste provides high adhesion (sticking) of the medicinal components included in the composition to the wall of the pit and, consequently, ensures long-term deposition of all medical components of the ointment in the hole of the extracted tooth, necessary for the stimulation of regeneration processes in periodontal tissues.

Benzocaine is a low-toxic, hypoallergenic and highly effective mestnorazdrajayuschie substance. Lelinwalla ointment used as the basis for mitigation and fixation of the total composition. Ointment independently resolved in the hole in 2-3 days.

The claimed ointment for the treatment and prevention of alveolitis is prepared as follows. Prepare all the necessary components in the prescription number. The ointment is prepared by simple mixing of the components in the specified proportions at room temperature.

The iodine solution obtained by dissolving 0.3 wt.% crystalline iodine in aqueous solution of 0.5 wt.% potassium iodide, Immobiliser 0.5 wt.% "POLYSORB" for 15 minutes, then injected to 42.5 wt.% analinvasion ointments, thoroughly mixed, then the resulting composition is administered to 5.8 wt.% of benzocaine and 42.5 wt.% solcoseryl is antalinos adhesive paste, followed by stirring with addition of distilled water to form a homogeneous mass.

The shelf life of the resulting ointment is not less than 1 year. Parameters ointment stable during storage. The ointment is a light yellow mass with a pleasant smell of vaseline.

The proposed solution allows to obtain a inexpensive, cost-effective means for the prevention and treatment of alveolitis with high efficiency, and to reduce the treatment time. Therapeutic effect of the proposed drug tested throughout the range of the quantitative content components. Complications and side effects when using this tool have been identified. The ointment is well fixed in the hole even in the presence of blood and exudate, providing long-term deposition of drugs into the hole of the extracted tooth.

The claimed ointment was clinically tested on the basis of the regional clinical dental clinic Stavropol.

Examples of specific performance.

Example 1. Patient A., 31, AMB. map No. 10731.

The patient was contacted 2 days after removal of the 37 tooth of the lower jaw on the left complaining of severe pain, radiating to the ear, temple, bad breath, difficulty opening the mouth.

Objectively: General condition is satisfactory, low-grade temperature, trism masticatory muscles, the average degree in the mouth - hole remote 37 tooth without clot, bone wall lunch is covered with a dirty-gray fetid bloom, palpation at transition crease sharply painful. On the radiograph residues roots 37 tooth was not found.

On the basis of objective data and the collected history diagnosed with acute post-extraction alveolitis holes 37 of the tooth of the lower jaw to the left.

Treatment. Under local anesthesia performed curettage, well washed with an antiseptic solution, introduced the claimed ointment. Recovery the patient came on the day 3 after the start of treatment.

Example 2. Patient S., aged 45, AMB. map No. 11247.

The purpose of the following rational prosthetics patient C. was produced simultaneously removing 24 and 25 of the tooth with a diagnosis of "chronic periodontitis". During the operation, the tip fakturierung buccal root 24 tooth was removed by sawing the alveolar part of the maxilla. Due to the high likelihood of postoperative inflammatory complications, prevention alveolitis, wells extracted teeth were filled with the claimed ointment.

Outcome: according to clinical observation, the healing of the hole remote teeth 24 and 25 painless, without suppuration, hyperemia and edema, complete epithelialization of the wounds has come through the 7 days.

Clinical trials offer the ointment was performed in 116 patients in the period from 2006 to 2009, the basis of surgical Department of the regional clinical is the dental clinic of the city of Stavropol). A single patient who used the claimed ointment for the treatment and prevention of alveolitis, inflammatory complications were noted, and the time of regeneration of the bone of the alveolus of the tooth, on average, decreased by 40%.

The data obtained showed high anti-inflammatory and regeneration efficiency of the developed ointments that are designed to accelerate bone healing wounds, to prevent the development of inflammatory complications and shorten the recovery period of patients with alveolitis.

Ointment for the treatment and prevention of alveolitis containing benzocaine, iodine crystal, an aqueous solution of potassium iodide, analinvasion basis and distilled water, characterized in that it further comprises solcoseryl dental adhesive paste and "POLYSORB" in the following ratio, wt.%:

Lelinwalla ointment40,5-42,5
Iodine crystalof 0.1-0.3
An aqueous solution of potassium iodide0,4-0,5
Solcoseryl dental adhesive paste40,5-42,5
Benzocaine3,8-5,
POLYSORB0,3-0,5
Distilled waterrest



 

Same patents:

FIELD: medicine.

SUBSTANCE: invention can be used in biotechnology, and can be used in practical health services for preventing seasonal influenza incidence in adults and children by a live influenza intranasal vaccine of the A/Solomon Islands/03/2006 (H1N1) influenza virus. Vaccine strain of B/60/Florida/04/181 (H1N1) is a reassortant prepared by cross breeding an epidemic B/Florida/07/04 virus and a cold-adapted thermally sensitive B/USSR/60/69 virus being a human-safe attenuation donor. The vaccine strain B/60/Florida/04/181 (H1N1) strain replicates actively in growing chicken embryos at optimum temperature 32°C, is characterised by thermal sensitivity and cold adaptation. The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor.

EFFECT: strain is areactogenic for adults and children in intranasal introduction.

2 tbl

FIELD: medicine.

SUBSTANCE: vaccine strain of A/17/Solomon Islands/06/9 (H1N1) is a reassortant prepared by cross breeding an epidemic A/Solomon Islands/03/2006 (H1N1) virus and a cold-adapted thermally sensitive A/Leningrad/134/17/57 (H2N2) virus being a human-safe attenuation donor. The vaccine strain A/17/Solomon Islands/06/9 (H1N1) strain replicates actively in growing chicken embryos at optimum temperature 32°C, is characterised by thermal sensitivity and cold adaptation, The reassortant has inherited the genes coding surface virus antigens - hemagglutinin (HA) and neuraminidase (NA) from an epidemic parent virus, and six genes coding internal non-glycosylated proteins from the attenuation donor. The A/17/Solomon Islands/06/9 strain is areactogenic for adults and children in intranasal introduction.

EFFECT: applicability in practical health services for preventing seasonal influenza incidence in adults and children by a live influenza intranasal vaccine of the strain of said influenza virus.

1 dwg, 3 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to compounds of formula (I) where R1 is chosen from ethyl, n-propyl, isopropyl or isobutyl, and to its pharmaceutically acceptable salts. Besides, the invention refers to a pharmaceutical composition on the basis of said compounds used for treating a hepatitis C virus (HCV) mediated disease, and also to a method of treating the hepatitis C virus (HCV) mediated disease, and to the method of selective O-acylation nucleoside II for producing O-acyl nucleoside I in an alkaline reaction medium including the stages: (i) dissolution of II and DMAP in a heterogeneous mixture of water and a solvent and addition of a water base for pH control between approximately 7.5 to approximately 12; (ii) optional addition of a sufficient amount of saturated aqueous NaCl for preparing a diphase reaction mixture; (iii) addition of an acidating agent and an accessory base sufficient for pH preservation between approximately 7.5 to approximately 12; (iv) reaction monitoring and interruption of adding said acidating agent and said base after sufficient conversion provided; (v) optional contact of O-acylnucleoside with the pharmaceutically acceptable acid to produce a pharmaceutically acceptable salt.

EFFECT: production of the pharmaceutical composition for treating the hepatitis C virus (HCV) mediated disease.

9 cl, 2 tbl, 8 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the new fused pyrimidines of formula (I) and to their pharmaceutically acceptable salts exhibiting P13 kinase inhibitor properties; in formula (I), A represents a thiophen ring; n=1; R1 represents a group of formula , where m=1; R30 represents hydrogen; R4 and R5 together with N atom whereto attached form a 5- or 6-members saturated N-containing heterocyclic group which includes 1 additional heteroatom selected from N which is unsubstituted or substituted by C1-C3alkyl which can be substituted by OH; S(O)2C1-3alkyl; C(O)N(diC1-C3alkyl); N(CH3)2; CON(CH3)-CH2CH2OCH3; N(CH3)-CH2CH2OCH3; -C(O)morpholine or morpholine; R2 is selected from where R6 and R7 together with nitrogen atom whereto attached form a morpholine group which is unsubstituted; and R3 represents an indole group which is unsubstituted.

EFFECT: production of the compounds of formula (I), a pharmaceutical composition, their application for preparing a drug and a method of inhibition.

9 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula (I) where values of the substitutes are disclosed in the patent claim.

EFFECT: compounds can be applied for treating the infections caused by Pneumovirinae subfamily viruses (RSV, PCB).

53 cl, 502 ex, 11 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of biotechnoloy and deals with compositions for production of vaccine against Neisseria meningitidis, which represent conjugates of different serogroups of N. meningitides with protein-carrier, selected from bacterial toxins or anatoxins, with specified size, in determination by gel-penetrating chromatography (GPC) and/or definite molecular weight in determination by exclusion chromatography with detecting by photometry of multi-angle light diffusion (SEC-MALS).

EFFECT: conjugates of claimed sizes, representing saccharide fragments, are applied in combination into polyvalent vaccine.

6 cl, 11 dwg

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to biotechnologies and represents immunogenic composition - emulsion of type "oil-in-water", which contains water solution, containing antigen or immunogen, nonionogenic lipophilic ethoxylated C9-C22 alcohol of fatty series, ethoxylated 1-4 EO, mineral oil, which contains linear or branched carbon chain, which contains from 15 to 32 atoms of carbon, nonionic hydrophilic surface-active substance, which represents ethoxylated C9-C22 alcohol from fatty series, ethoxylated 5-21 EO. Total concentration of surface-active substances (by weight per volume of emulsion) constitutes from 0.2% to 6.5%, concentration of oil phase, which includes oil(s) and surface-active substances constitutes from 2% to 50% and temperature of phase inversion (PIT) constitutes from 25°C to 65°C.

EFFECT: invention can be applied as adjuvant.

19 cl, 5 tbl, 11 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of medicine and deals with composition of pharmaceutical composition with anti-tuberculosis action. Essence of method: pharmaceutical composition, made in one of solid medicinal forms, includes therapeutically efficient quantity of activesubstance, as such containing combination of isoniazide, sodium para-aminosalicylate and pyridoxine hydrochloride with the following ratio of active substance ingredients, wt %: sodium para-aminosalicylate - 36.8%-90.41%; isoniazide - 1.08%-3.38%; pyridoxine hydrochloride - 0.007%-3.30%.

EFFECT: application of claimed pharmaceutical composition with anti-tuberculosis action will ensure high concentration of active medications in blood serum with longer term of preservation, make it possible to prevent formation of drug resistance of mycobacteria to isoniazide, as well as reduce side effects of isoniazide on central nervous system, which will assist in extension of anti-tuberculosis medications arsenal for therapy of tuberculosis, including drug-resistant form.

4 cl, 3 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a compound of formula (I) or stereoisomer thereof, or salt thereof, as well as synthesis method thereof and intermediate compounds of formulae (II) and (III) used in this method.

EFFECT: novel compound which can be used to produce HIV protease inhibitors.

23 cl, 2 tbl, 1 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel compounds of formula I, which are HSP90 (heat-shock proteins) inhibitors and can be used to prepare a medicinal agent for treating tumorous diseases affected by HSP90 inhibition. In formula I R1 denotes Hal, H, OA or A, R2, R3 each independently denotes -O-(X)s-Q, -NHCO-(X)s-Q, -CONH-(X)s-Q, -NH(CO)NH-(X)s-Q, -NH(CO)O-(X)s-Q, -NHSOr(X)s-Q, NHCOA, Hal, Het or H, where, if R2=H, then R3≠H, or if R3=H, then R2≠H, R4 denotes H, R5 denotes H, Hal, A, OA, (CH2)nCOOH, (CH2)nCOOA, O(CH2)oCONH2, NHCOOA, NHCO(CH2)nNH2, NHCONHA or O(CH2)oHet1, A denotes a straight or branched alkyl containing 1-10 carbon atoms, in which 1-5 hydrogen atoms may be substituted with F, Cl and/or Br, X denotes a straight or branched C1-C10 alkylene which is unsubstituted or substituted once, twice or thrice by A, O A, OH, Hal, CN, COOH, COOA, CONH2, NH2, NHCOA, NHCOOA, Q denotes H, Ar or Het, Ar denotes phenyl which is unsubstituted or substituted once, twice or thrice with A, OA, OH, NO2, Hal, CN, (CH2)nCOOH, (CH2)nCOOA and/or tetrazole, Het denotes a cyclic saturated or aromatic 5-6-member heterocycle containing 1-2 N and/or O atoms, optionally condensed with a benzene ring which may be substituted once, twice or thrice with A, OA, OH and/or =O (carbonyl oxygen), Het1 denotes a monocyclic saturated, unsaturated or aromatic heterocycle containing 1-2 N and/or O atoms, which may be mono- or disubstituted with A, OA, OH, Hal and/or =O (carbonyl oxygen), Hal denotes F, Cl, Br or I, n equals , 1, 2, 3 or 4, o equals 1, 2 or 3, s equals 0, 1 or 2.

EFFECT: high efficiency of using said derivatives.

4 cl, 4 dwg, 1 tbl, 29 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to new compounds of formula (I) and to their pharmaceutically acceptable salts exhibiting PI3 kinase inhibitor activity. In the formula (I), A represents a thiophen ring; n=1; R1 represents , where m=1; R30 represents H; R4 And R5 together with N atom whereto attached form a 5- or 6-members N-containing heterocyclic group which includes 0 or 1 additional heteroatom selected from N and O which is unsubstituted or substituted by one or more substitutes selected from C1-6alkyl, C1-6alkoxy, -N(R"')-alk-OR, -alk-OR, -O-alk-OR, -alk-C(O)NR2, -C(O)NR2, -alk-Het, -N(R)-Het, -O-Het, -N(R)-C(O)- alk-OR, -NR-S(O)2R, -N(R)-alk-S(O)2R, -N(R)-alk-OR, -alk-NR'R", -N(R"')-S(O)2R, S(O)2R"', -S(O)2-alk-ORf 5- or 6-members N-containing heterocyclic group, 5- or 6-members N-containing heteroaryl group which includes 0 or 1 additional heteroatom selected from N, O or S, oxo(=O), -SO2NR2, -SO2-alk-NR2 where alk means a C1-6alkylene chain; Het means a 5- or 6-members N-containing heteroaryl group or furan optionally substituted by C1-6alkyl; R means H or C1-6alkyl, or when 2 groups R are bound with N, they together with N atom form a saturated 5- or 6-members N-containing heterocyclic group; each R' and R" means independently H, C1-6alkyl or C1-6alkoxy; R'" represents C1-6alkyl, a 5- or 6-merous saturated N-containing heterocyclic group, or a 5- or 6-merous N-containing heteroaryl group; R2 means where R6 and R7 together with N atom whereto attached form a morpholine group; R3 represents an indazole group.

EFFECT: development of the effective method of preparing the compounds of formula (I), and their application for preparing a drug, a pharmaceutical composition, and a method of inhibition.

10 cl, 6 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to the new fused pyrimidines of formula (I) and to their pharmaceutically acceptable salts exhibiting P13 kinase inhibitor properties; in formula (I), A represents a thiophen ring; n=1; R1 represents a group of formula , where m=1; R30 represents hydrogen; R4 and R5 together with N atom whereto attached form a 5- or 6-members saturated N-containing heterocyclic group which includes 1 additional heteroatom selected from N which is unsubstituted or substituted by C1-C3alkyl which can be substituted by OH; S(O)2C1-3alkyl; C(O)N(diC1-C3alkyl); N(CH3)2; CON(CH3)-CH2CH2OCH3; N(CH3)-CH2CH2OCH3; -C(O)morpholine or morpholine; R2 is selected from where R6 and R7 together with nitrogen atom whereto attached form a morpholine group which is unsubstituted; and R3 represents an indole group which is unsubstituted.

EFFECT: production of the compounds of formula (I), a pharmaceutical composition, their application for preparing a drug and a method of inhibition.

9 cl, 6 ex

FIELD: chemistry.

SUBSTANCE: invention relates to novel derivatives of 2-(phenyl)-1H-phenanthro[9,10-d]imidazole of general formula B , or pharmaceutically acceptable salts thereof, where R3 denotes and R6 is selected from a group comprising (2) F; (3) Cl; (4) Br; (5) I; (8) C3-6cycloalkyl; (9) R12 -O-; R12 is selected from a group comprising (2) C1-4alkyl, (3) C3-6cycloalkyl; (4) C3-6cycloalkyl-C1-4alkyl-; said C1-4alkyl is optionally substituted with 1-3 substitutes independently selected from a group comprising F, CI, Br and I. The invention also relates to specific compounds of general formula B, a pharmaceutical composition based on compounds of formula B, and a method of treatment using compounds of formula B.

EFFECT: novel derivatives having inhibitory activity on microsomal prostaglandin E synthase-1.

12 cl, 16 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: present invention refers to medicine, namely to a new application of common indole derivatives for preparing a drug exhibiting the properties of a protein kinase C inhibitor. A preferential indole derivative is 1-methyl-2-phenylthiomethyl-3-carbethoxy-4-dimethylaminomethyl-5-oxy-6-bromindole hydrochloride.

EFFECT: compounds are effective protein kinase C inhibitors that allows them being used in treating inflammatory diseases, ischemia, cardiovascular diseases, dermatological diseases, asthma, diabetes.

3 cl, 3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: offered is an application of 2-hydroxy-3-methyl-6-(1-methylethenyl)cyclo-hex-3-enone (compound of formula 1) as an analgesic. The agent can be produced of an available natural compound α-pinene.

EFFECT: agent exhibits high activity, low toxicity, can be used in medicine.

4 ex, 2 tbl

FIELD: chemistry.

SUBSTANCE: invention relates to organophosphorous chemistry and pharmaceuticals and pertains to novel dialkyl-β-(o-salicyloyl)ethylphosphates based on salicylic acid of formula , having antithermic activity.

EFFECT: compound does not have damaging effect on the mucous coat of the stomach and has low toxicity.

1 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: invention refers to new amino acid derivatives of formula (I), , in which R-groups have the following value: -R1 is -H;-R2 is -C(O)R15 or -SO2R15; -R3 is -H;-R4 is -H or -(1-4C)alkyl; -R6 is -H; -R7 is -H; -R8 is -H, cyanogroup, halogen, nitrogroup; -(1-6C)alkyl optionally substituted by amino group, hydroxyl or halogen; -heteroaryl representing a 5 or 6-members aromatic ring containing one or more heteroatoms N optionally substituted by -(1-4C) alkyl; -C(R16)NOR16, -C(O)N(R17)2, -C(O)R18 or -C(O)OR19; -R9 is -H; -R10 is -H or -(1-4C)alkyl; -R11 is -H; -R12 is -H; -R13 is -H; -R14 is -H; -R15 is -H; -(1-6C)alkyl, -(2-6C)alkynyl, -O(2-6C)alkyl) all optionally substituted by one or more, halogen, cyanogroup or 5-members heteroaryl where 5-members heteroaryl represents an aromatic ring containing one or more heteroatoms selected from a group including N, O or S; -(hetero)aryl representing 5 or 6-members aromatic ring system containing one or more heteroatoms selected from group including N, O or S, optionally substituted by -(1-4C)alkyl, halogen or NH2; -NH2, -(di)(1-4C)alkylamihogroup, -(1-4C)alkylamihogroup or -NR16OR16; R16 is -H or -(1-4C)alkyl; -R17 is -H or -(1-6C)alkyl optionally substituted by halogen, or 5 or 6-members heteroaryl or aryl optionally substituted by halogen, -(1-4C)alkyl or -(1-4C)alkoxygroup where heteroaryl represents an aromatic ring containing one or more heteroatoms selected from the group including N, O or S; -R18 is -H or -(1-4C)alkyl; -R19 is -H or -(1-6C)alkyl.

EFFECT: compounds of this invention are high-specific to glucocorticoid receptor and can be used for treating inflammatory diseases.

6 cl, 58 ex

Novel compounds // 2419608

FIELD: chemistry.

SUBSTANCE: invention relates to use of compounds of general formula

, where m equals 0, 1, 2 or 3; each R1 independently denotes halogen, cyano, hydroxyl, C3-C6cycloalkyl, C1-C6alkoxy, C1-C6halogenalkyl, C1-C6halogenalkoxy, -NR9R10, C1-C6alkylthio, C1-C6alkylcarbonyl, phenyl or C1-C6alkyl; Z denotes a bond or a (CH2)q group, where q equals 1 or 2; Z2 denotes a bond or a CH2 group, provided that both Z1 and Z2 do not denote a bond at the same time; Q denotes an oxygen or sulphur atom or a CH2 or a NH group; R2 denotes a group , n equals 0; each R4, R5, R6 and R7 independently denotes a hydrogen atom or a C1-C6alkyl group, or R4, R5, R6 and R7 together denote a C1-C4alkylene chain which binds two carbon atoms to which they are bonded to form a 4-7-member saturated carbocycle, or each R5, R6 and R7 denotes a hydrogen atom, and R4 and R8 together with carbon atom to which they are bonded form a 5-6-member saturated carbocycle; R8 denotes a hydrogen atom, a C1-C6alkyl group, or is bonded to R4 as defined above; each R9 and R10 independently denotes a hydrogen atom; R15 denotes -OC(O)NR17R18 or -NHC(O)R20; t equals 0, 1, 2 or 3; each R16 independently denotes a halogen, cyano, hydroxyl, C3-C6cycloalkyl, C1-C6alkoxy, C1-C6halogenalkyl, C1-C6halogenalkoxy, -NR21R22, C1-C6alkylthio, C1-C6alkylcarbonyl, phenyl or C1-C6alkyl; each R17 and R18 independently denotes a hydrogen atom or C1-C6alkyl group; R20 denotes C1-C6alkyl, C3-C6cycloalkyl, C5-C6cycloalkenyl, phenyl or a 5-6-member nitrogen-containing heterocyclic ring system which may be substituted with C1-C6alkyl; each R21 and R22 independently denotes a hydrogen atom; or to pharmaceutically acceptable salts or solvates thereof in preparing a medicinal agent for use in treating inflammatory diseases. The invention also relates to use of compounds of formula (I) in preparing a medicinal agent for use in treating respiratory tract diseases.

EFFECT: use of biologically active compounds, capable of modulating CCR1 receptor activity.

24 cl, 63 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to water solution of paracetamol for its application in perfusion with pH between 4.5 and 6. Solution contains compound, stabilising paracetamol in solution, which consists of glucose in concentration between 0.5% wt/vol and 3.3% wt/vol. Water paracetamol solution in accordance with the invention can be sterilised by heating or filtration.

EFFECT: injectable paracetamol solution in accordance with the invention has high stability, does not acquire colour in the course of time and has minimal content of admixtures.

7 cl, 3 tbl, 3 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to field of pharmacology and medicine and deals with application of 4,7-dimethyl-2-(prop-1-enyl)-3,4,4a,5,8,8a-hexahydro-2H-chromen-4,8-diol as analgesic.

EFFECT: medication possesses high activity, low toxicity and can be obtained from available natural compound of α-pinene.

1 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to neurology, and can be used in complex rehabilitation of the patients with central spastic paresis of upper extremities. For this purpose, first under block anaesthesia of branches of a brachial plexus, hand bracing is performed from an axillary approach. In bracing, a rigid bandage is applied to a level of the lower one-third of forearm 2 cm higher than a wrist joint. It is followed with physioprocedures every 15-30 minutes in the following order: paraffin-ozokerite applications or cryotherapy during 20 min, electrical myostimulation of extensor muscles of hand and fingers, massage of the affected extremities, physiotherapy exercises, mirror therapy. Thereafter, the hand is placed in the brace and fixed with an elastic bandage. The bracing time is 3-4 hours 1-2 times a day. A number of the physioprocedures of each type makes 15-20 procedures in the course. The bracing period is 3 weeks to 3 months, and the brace is used till muscle tone recovery, and also active finger extension. For one year after the suffered stroke, the rehabilitation courses are repeated for 3-4 times a year, further the therapeutic courses are performed 2 times a year.

EFFECT: method allows ensuring considerable recovery of motor functions disordered by a local brain damage and activation of neuroplasticity mechanisms of the central nervous system for a shorter period of time in the given category of patients due to optimal selection of a therapeutic regimen and more effective bracing.

2 ex

Up!